口服异维A酸治疗痤疮的疗效与不良事件:系统综述
异维A酸可临床相关地减少痤疮皮损计数,且减少幅度始终大于对照;但不良事件频率约为对照的两倍(751例次 vs 388例次),过半为皮肤干燥相关。
要点
- 异维A酸减少痤疮皮损计数的幅度始终大于安慰剂、口服抗生素或其他对照。
- 不良事件频率约为对照的两倍(751 vs 388例次),过半为皮肤干燥相关。
- 因不良事件退出试验者12例,包括Stevens-Johnson综合征、唇炎、皮肤干燥等。
核心结论
- 异维A酸可有效减少痤疮皮损计数,但不良事件常见。
研究设计与样本
- 系统综述,检索MEDLINE、Embase、Cochrane Central及相关网页和参考文献,纳入比较异维A酸与对照(安慰剂或其他疗法)的随机对照试验。
主要发现
- 所有试验中异维A酸均以临床相关幅度减少痤疮皮损计数,且减少幅度始终大于对照(安慰剂2项、口服抗生素7项、其他对照2项)。
- 在总体低偏倚风险的试验中,3项中有2项显示异维A酸与对照之间差异有统计学意义。
- 异维A酸的不良事件频率(751例次)约为对照(388例次)的两倍,过半不良事件为皮肤科相关且与干燥有关。
关键数值与推荐
- 因不良事件退出试验的12例患者中,事件包括Stevens-Johnson综合征、唇炎、皮肤干燥、痤疮加重、畏光、肝酶升高、食欲下降、头痛和情绪低落。
临床怎么用
- 异维A酸可用于中度至重度痤疮以减少皮损,但需预期并监测常见不良事件,尤其是皮肤干燥相关事件。
局限性
- 原文未系统报告各试验的具体样本量、效应量、置信区间及P值等详细数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite many years of clinical use of isotretinoin, a comprehensive review of evidence for isotretinoin therapy in patients with acne is lacking. We searched MEDLINE, Embase, Cochrane Central, relevant web pages and bibliographies for randomized controlled trials in acne evaluating isotretinoin vs. control (placebo or other therapy). Data were extracted and summarized descriptively. Eleven trials were identified (total 760 patients randomized), containing mostly men. Mean treatment ages ranged from 18 to 47·9 years and participants generally had moderate-to-severe acne. Across all trials, isotretinoin therapy reduced acne lesion counts by a clinically relevant amount, and always by a greater amount than control, which was either placebo (two studies), oral antibiotics (seven studies) or other control (two studies). Across trials with an overall low risk of bias, two of three demonstrated statistically significant differences between isotretinoin and control. The frequency of adverse events was twice as high with isotretinoin (751 events) than with control (388 events). More than half of all adverse events were dermatological and related to dryness. Adverse events from isotretinoin causing participant withdrawal from trials (12 patients) included Stevens-Johnson syndrome, cheilitis, xerosis, acne flare, photophobia, elevated liver enzymes, decreased appetite, headaches and depressed mood. This review suggests that isotretinoin is effective in reducing acne lesion counts, but adverse events are common. This study was registered with PROSPERO number CRD42015025080.
引用
- Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2017. PMID: 28542914. doi:10.1111/bjd.15668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。